Cardinal Health's CFO Moved $9.9 Million of Stock. Here's What Long-Term Investors Should Know
Key Points
The transaction involved 42,000 shares with a total value of ~$9.9 million on August 18.
Following the sale, the executive retains 20,495 shares held directly, with no reported indirect ownership.
The transaction was executed after the stock achieved a 57% one-year total return as of the August 18 transaction date.
- 10 stocks we like better than Cardinal Health ›
Aaron E. Alt, the chief financial officer of Cardinal Health, Inc. (NYSE:CAH), sold 42,000 shares of common stock on August 18, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $9.9 million |
| Shares sold | 42,000 |
| Post-transaction shares (directly held) | 20,495 |
| Post-transaction value | $4.82 million |
Transaction value based on SEC Form 4 weighted average sale price ($236.34); post-transaction value based on the August 18 market close ($234.98).
Key questions
- What was the proportional impact of this sale on the insider's direct investment?
The disposal of 42,000 shares resulted in a reduction of the CFO's direct equity holdings, leaving a remaining balance of 20,495 shares. - How did the execution price compare to the market's valuation on the transaction date?
The shares were sold at a weighted-average price of $236.34, slightly higher than the $234.98 market close on August 18. - What is the current scale of the insider's remaining direct exposure?
The remaining 20,495 shares represent a total market value of $4.82 million based on the market close at the time of the transaction, while the company's broader insider ownership level is reported at 0.0088%.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-19) | $234.85 |
| Market Capitalization | $55.0 billion |
| Revenue (TTM) | $254.2 billion |
| Net Income (TTM) | $1.7 billion |
Company Snapshot
- Cardinal Health operates as a global, integrated healthcare services and products provider, delivering pharmaceutical distribution, medical supplies, and healthcare solutions across the United States, Canada, Europe, Asia, and international markets.
- The company generates revenue through its two core operating divisions--Pharmaceutical and Medical--which provide distribution, logistics, and specialized healthcare services to institutional and individual customers.
- Cardinal Health serves a diverse customer base, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical laboratories, physician practices, and patients receiving home-based care.
Cardinal Health is one of the largest healthcare services and products companies globally, with TTM revenue of $254.2 billion. The company maintains a competitive position through its integrated distribution network, broad customer relationships, and diversified service offerings across pharmaceutical and medical segments. Cardinal Health's scale and operational infrastructure enable it to serve as a critical intermediary within the healthcare supply chain, supporting healthcare providers and patients across multiple geographies and care settings.
What this transaction means for investors
Alt held 26,408 shares before an Aug. 4 performance-unit award for Cardinal Health executives and then had 20,495 once the Aug. 18 selling was done, which brought in roughly $9.9 million and marked a slight reduction in the overall stake.
It's not unusual to see an executive manage their awards in such a way, and more important for long-term investors is what Alt ultimately heads up as CFO. Fourth-quarter EPS came in at $2.91, up 40%, but $0.31 of it was a one-time tariff refund, so Alt stripped it out and set the fiscal 2026 comparison at $10.95 rather than the $11.26 the company actually reported. Fiscal 2027 guidance of $12.40 to $12.60 is 13% to 15% growth against $10.95. Measured against $11.26, it's closer to 10% to 12%. "We did what we said we would do," Alt told analysts on the Aug. 11 call. Beyond those projections, he noted that the firm's plans and priorities remain unchanged, with planned capital expenditures of about $700 million, no significant actions needed to protect the firm's balance sheet, and at least $1 billion in share repurchases expected in the 2027 fiscal year.
Should you buy stock in Cardinal Health right now?
Before you buy stock in Cardinal Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cardinal Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $429,223!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,318,055!*
Now, it’s worth noting Stock Advisor’s total average return is 965% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 23, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
